4.2 Article

Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells

Journal

STEM CELL RESEARCH
Volume 14, Issue 1, Pages 95-104

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.scr.2014.11.007

Keywords

-

Funding

  1. Intramural Research Programs of the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute, NIH
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006107, ZIAHL006217, ZIAHL006106, ZIAHL006205, Z01HL002342, ZIAHL006218, ZIAHL006172] Funding Source: NIH RePORTER
  3. NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZICHG200348, ZIAHG000030] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Mesenchymal stromal cells (MSCs) support the growth and differentiation of normal hematopoietic stem cells (HSCs). Here we studied the ability of MSCs to support the growth and survival of leukemic stem cells (LSCs) in vitro. Primary leukemic blasts isolated from the peripheral blood of 8 patients with acute myeloid leukemia (AML) were co-cultured with equal numbers of irradiated MSCs derived from unrelated donor bone marrow, with or without cytokines for up to 6 weeks. Four samples showed CD34(+) CD38(-) predominance, and four were predominantly CD34(+) CD38(+). CD34(+) CD38(-) predominant leukemia cells maintained the CD34(+) CD38(-) phenotype and were viable for 6 weeks when co-cultured with MSCs compared to co-cultures with cytokines or medium only, which showed rapid differentiation and loss of the LSC phenotype. In contrast, CD34(+) CD38(+) predominant leukemic cells maintained the CD34(+) CD38(+) phenotype when co-cultured with MSCs alone, but no culture conditions supported survival beyond 4 weeks. Cell cycle analysis showed that MSCs maintained a higher proportion of CD34(+) blasts in G0 than leukemic cells cultured with cytokines. AML blasts maintained in culture with MSCs for up to 6 weeks engrafted NSG mice with the same efficiency as their non-cultured counterparts, and the original karyotype persisted after co-culture. Chemosensitivity and transwell assays suggest that MSCs provide pro-survival benefits to leukemic blasts through cell-cell contact. We conclude that MSCs support long-term maintenance of LSCs in vitro. This simple and inexpensive approach will facilitate basic investigation of LSCs and enable screening of novel therapeutic agents targeting LSCs. Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Hematology

Next-generation CAR T cells to overcome current drawbacks

Stefan Lundh, Sayantan Maji, J. Joseph Melenhorst

Summary: CAR T-cell therapy, as a rapidly emerging treatment option in oncology, has shown significant efficacy and potential for cure in certain relapsed/refractory patients with hematologic malignancy. However, there are various barriers for widespread adoption of CAR T therapy, including cellular manufacturing limitations, adverse events post-infusion, and host rejection of non-human CARs. Future clinical trials need to address unique mechanisms of relapse in different hematologic diseases to enhance the efficacy of CAR T treatment.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

Article Orthopedics

Preliminary Report of a Hybrid Total Ankle Arthroplasty Combining a Stemmed Intramedullary Tibial Component With Chamfer-Cut Talar Dome

Philip Basile, Samantha A. Miner, Jordan W. Crafton, Bryon McKenna

Summary: This article presents a hybrid technique for total ankle arthroplasty using a stemmed intramedullary tibial component and a chamfer-cut talar component. The study shows that this technique is reproducible, accurate, and safe, with promising preliminary outcomes.

JOURNAL OF FOOT & ANKLE SURGERY (2022)

Article Multidisciplinary Sciences

Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells

J. Joseph Melenhorst, Gregory M. Chen, Meng Wang, David L. Porter, Changya Chen, McKensie A. Collins, Peng Gao, Shovik Bandyopadhyay, Hongxing Sun, Ziran Zhao, Stefan Lundh, Iulian Pruteanu-Malinici, Christopher L. Nobles, Sayantan Maji, Noelle Frey, Saar Gill, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, David E. Ambrose, Megan M. Davis, Joseph A. Fraietta, Jennifer L. Brogdon, Regina M. Young, Anne Chew, Bruce L. Levine, Donald L. Siegel, Cecile Alanio, E. John Wherry, Frederic D. Bushman, Simon F. Lacey, Kai Tan, Carl H. June

Summary: CAR T cells redirected to target CD19 demonstrated long-lasting potential and clonal stability in two patients with chronic lymphocytic leukaemia. Highly activated CD4(+) cells emerged and dominated the CAR T cell population at later time points. These unexpected CAR T cell populations provide novel insights into anti-cancer response and long-term remission in leukaemia.

NATURE (2022)

Article Hematology

Long-term eltrombopag for bone marrow failure depletes iron

David J. Young, Xing Fan, Emma M. Groarke, Bhavisha Patel, Ronan Desmond, Thomas Winkler, Andre Larochelle, Katherine R. Calvo, Neal S. Young, Cynthia E. Dunbar

Summary: EPAG treatment for aplastic anemia and immune thrombocytopenia can result in iron depletion over time. This study found that duration of EPAG exposure correlated with reduction in ferritin levels and showed faster iron clearance compared to historical responders. Baseline ferritin and duration of therapy were associated with risk of iron depletion, but did not affect treatment response or relapse risk.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

Editorial Material Hematology

Do CARs finally hit the CLL road?

Arnon P. Kater, J. Joseph Melenhorst

Summary: This study summarizes a phase 1/2 dose-escalation chimeric antigen receptor T (CART) trial for patients with chronic lymphocytic leukemia (CLL). The CART19 cells treatment showed promising results, with most patients experiencing cytokine release syndrome and neurotoxicity, but achieving long-lasting complete responses and undetectable minimal residual disease in a subset of patients.

BLOOD (2022)

Editorial Material Cell Biology

B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?

Gregory M. Chen, Jan Joseph Melenhorst, Kai Tan

Summary: CAR T cell therapies targeting CD19 and CD22 have shown success in treating B cell cancers, but not in non-B cell cancers. The interaction between CAR T cells and normal B cells may play a crucial role in determining clinical CAR T cell responses.

SCIENCE TRANSLATIONAL MEDICINE (2022)

Review Orthopedics

Time to Revision After Periprosthetic Joint Infection in Total Ankle Arthroplasty: A Systematic Review

Samantha A. Miner, John A. Martucci, Stephen A. Brigido, Lawrence DiDomenico

Summary: Although periprosthetic joint infection (PJI) is not common after total ankle arthroplasty (TAA), it poses a significant risk to implant failure. This systematic review aimed to evaluate the time to revision surgery after PJI in TAA patients. A total of 12 articles studying 3040 implants were included, and the average time to revision due to PJI was found to be 30.7 months. It is suggested to modify the current PJI classification to include early chronic and late chronic subgroups for better diagnosis and treatment of PJIs.

JOURNAL OF FOOT & ANKLE SURGERY (2023)

Editorial Material Oncology

Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation

Ziran Zhao, Jan Joseph Melenhorst

CANCER IMMUNOLOGY RESEARCH (2022)

Article Orthopedics

Tibial Component Subsidence in a Total Ankle System Comparing Standard Technique Versus a Hybrid Technique

Samantha A. Miner, Philip Basile, Jeremy Cook, Emily Cook, John Constantino

Summary: Total ankle arthroplasty (TAA) is an effective treatment for end-stage ankle arthritis, but concerns have been raised about early component loosening. A retrospective study compared the short-term outcomes of the tibial component between a standard TAA system and a hybrid technique. The rate of tibial component subsidence was low in both groups, and further studies are needed to explore factors that may contribute to early tibial component subsidence and implant failure.

JOURNAL OF FOOT & ANKLE SURGERY (2023)

Correction Multidisciplinary Sciences

Decade-long leukaemia remissions with persistence of CD4+ CAR T cells (vol 602, pg 503, 2022)

J. Joseph Melenhorst, Gregory M. M. Chen, Meng Wang, David L. L. Porter, Changya Chen, McKensie A. A. Collins, Peng Gao, Shovik Bandyopadhyay, Hongxing Sun, Ziran Zhao, Stefan Lundh, Iulian Pruteanu-Malinici, Christopher L. L. Nobles, Sayantan Maji, Noelle V. V. Frey, Saar I. I. Gill, Alison W. W. Loren, Lifeng Tian, Irina Kulikovskaya, Minnal Gupta, David E. E. Ambrose, Megan M. M. Davis, Joseph A. A. Fraietta, Jennifer L. L. Brogdon, Regina M. M. Young, Anne Chew, Bruce L. L. Levine, Donald L. L. Siegel, Cecile Alanio, E. John Wherry, Frederic D. D. Bushman, Simon F. F. Lacey, Kai Tan, Carl H. H. June

NATURE (2022)

Review Cell Biology

De Novo Generation of Human Hematopoietic Stem Cells from Pluripotent Stem Cells for Cellular Therapy

Jianyi Ding, Yongqin Li, Andre Larochelle

Summary: The ability to produce human hematopoietic stem cells (HSCs) in the laboratory holds great potential for cellular therapy of blood diseases. However, current differentiation protocols for generating HSCs from pluripotent stem cells (PSCs) lack clinical relevance and result in limited engraftment and differentiation capabilities. This review discusses how intrinsic cues and extrinsic environmental inputs have been integrated into PSC differentiation protocols to enhance the emergence of definitive hematopoiesis, and explores the role of genomics in advancing this field.

CELLS (2023)

Article Cell & Tissue Engineering

Modulation of WNT, Activin/Nodal, and MAPK Signaling Pathways Increases Arterial Hemogenic Endothelium and Hematopoietic Stem/Progenitor Cell Formation During Human iPSC Differentiation

Yongqin Li, Jianyi Ding, Daisuke Araki, Jizhong Zou, Andre Larochelle

Summary: Researchers optimized the differentiation of induced pluripotent stem cells into hematopoietic stem and progenitor cells by modulating specific signaling pathways, resulting in increased self-renewal and multilineage differentiation potential.

STEM CELLS (2023)

Article Hematology

Challenges and opportunities of CAR T-cell therapies for CLL *

Ziran Zhao, Celine Gregoire, Beatriz Oliveira, Kunho Chung, Jan Joseph Melenhorst

Summary: Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment of blood cancers by endowing T cells with antibody-like target cell recognition and lysis abilities. In chronic B lymphocytic leukemia (CLL), CAR T-cells have shown efficacy, but sustained remission remains a challenge. This article discusses the current treatment landscape in CLL, the role of CAR T-cells, and the improvements made through translational medicine.

SEMINARS IN HEMATOLOGY (2023)

Article Cell Biology

Positively charged patches: tonic for CAR fitness

Meraj H. Khan, Jan Joseph Melenhorst

Summary: This study reveals that the positively charged patches on the surface of CAR antigen-binding domain regulate CAR tonic signaling, offering a direction for further optimization of CAR.

CELL RESEARCH (2023)

Article Oncology

Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma

Kavita M. Dhodapkar, Adam D. Cohen, Akhilesh Kaushal, Alfred L. Garfall, Renee Julia Manalo, Allison R. Carr, Samuel S. McCachren III, Edward A. Stadtmauer, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Michael C. Milone, Madhav Dhodapkar

Summary: This study combined multiple approaches to study the tumor/immune cells in the tumor microenvironment of myeloma patients before and after BCMA CAR T therapy. The findings suggest that lower diversity of T-cell receptor repertoire, presence of hyperexpanded clones and exhausted phenotype, as well as the presence of specific cells in the bone marrow are associated with shorter progression-free survival following therapy. Conversely, longer progression-free survival is associated with an increased proportion of certain cells and the emergence of cells expressing marrow-residence genes. Tumor recurrence is associated with the emergence of new dominant clones.

BLOOD CANCER DISCOVERY (2022)

No Data Available